Quarterly report · Q3
4578.TEDINET S100PGE4
Period2022-01-01 → 2022-09-30
Filed2022-11-02
StandardIFRS
ConsolidatedYes
Data checks16 of 16 passed
Key figures · 61
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥1.27T | 2022-01-01 → 2022-09-30 | Cons. | Revenue IFRS |
| Revenue | ¥451.8bn | 2022-07-01 → 2022-09-30d | Cons. | Revenue IFRS |
| Revenue | ¥1.50T | 2021-01-01 → 2021-12-31 | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥1.11T | 2021-01-01 → 2021-09-30 | Cons. | Revenue IFRS |
| Revenue | ¥388.6bn | 2021-07-01 → 2021-09-30d | Cons. | Revenue IFRS |
| Operating income | ¥114.8bn | 2022-01-01 → 2022-09-30 | Cons. | Operating profit loss IFRS |
| Operating income | ¥47.7bn | 2022-07-01 → 2022-09-30d | Cons. | Operating profit loss IFRS |
| Operating income | ¥158.1bn | 2021-01-01 → 2021-09-30 | Cons. | Operating profit loss IFRS |
| Operating income | ¥47.0bn | 2021-07-01 → 2021-09-30d | Cons. | Operating profit loss IFRS |
| Profit before tax | ¥146.0bn | 2022-01-01 → 2022-09-30 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥53.2bn | 2022-07-01 → 2022-09-30d | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥163.6bn | 2021-01-01 → 2021-12-31 | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥166.3bn | 2021-01-01 → 2021-09-30 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥47.1bn | 2021-07-01 → 2021-09-30d | Cons. | Profit loss before tax IFRS |
| Net income (owners) | ¥111.0bn | 2022-01-01 → 2022-09-30 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥41.3bn | 2022-07-01 → 2022-09-30d | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥125.5bn | 2021-01-01 → 2021-12-31 | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥126.6bn | 2021-01-01 → 2021-09-30 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥35.2bn | 2021-07-01 → 2021-09-30d | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income | ¥113.9bn | 2022-01-01 → 2022-09-30 | Cons. | Profit loss IFRS |
| Net income | ¥42.4bn | 2022-07-01 → 2022-09-30d | Cons. | Profit loss IFRS |
| Net income | ¥130.0bn | 2021-01-01 → 2021-09-30 | Cons. | Profit loss IFRS |
| Net income | ¥36.3bn | 2021-07-01 → 2021-09-30d | Cons. | Profit loss IFRS |
| Total assets | ¥3.19T | at 2022-09-30 | Cons. | Assets IFRS |
| Total assets | ¥2.82T | at 2021-12-31 | Cons. | Assets IFRS |
| Total assets | ¥2.82T | at 2021-09-30 | Cons. | Total assets IFRS (5-year summary) |
| Total liabilities | ¥853.3bn | at 2022-09-30 | Cons. | Liabilities IFRS |
| Total liabilities | ¥775.7bn | at 2021-12-31 | Cons. | Liabilities IFRS |
| Net assets / equity | ¥2.33T | at 2022-09-30 | Cons. | Equity IFRS |
| Net assets / equity | ¥2.05T | at 2021-12-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥2.02T | at 2021-09-30 | Cons. | Equity IFRS |
| Net assets / equity | ¥1.88T | at 2020-12-31d | Cons. | Equity IFRS |
| Equity (owners) | ¥2.30T | at 2022-09-30 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥2.01T | at 2021-12-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥1.98T | at 2021-09-30 | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Cash & equivalents | ¥477.3bn | at 2022-09-30 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥410.7bn | at 2021-12-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥448.7bn | at 2021-09-30 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥356.9bn | at 2020-12-31d | Cons. | Cash and cash equivalents IFRS |
| Operating cash flow | ¥171.1bn | 2022-01-01 → 2022-09-30 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥228.9bn | 2021-01-01 → 2021-12-31 | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥197.2bn | 2021-01-01 → 2021-09-30 | Cons. | Net cash provided by used in operating activities IFRS |
| Investing cash flow | −¥60.4bn | 2022-01-01 → 2022-09-30 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥95.3bn | 2021-01-01 → 2021-12-31 | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥33.0bn | 2021-01-01 → 2021-09-30 | Cons. | Net cash provided by used in investing activities IFRS |
| Financing cash flow | −¥84.0bn | 2022-01-01 → 2022-09-30 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | −¥95.8bn | 2021-01-01 → 2021-12-31 | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | −¥83.7bn | 2021-01-01 → 2021-09-30 | Cons. | Net cash provided by used in financing activities IFRS |
| EPS (basic) | ¥204.65 | 2022-01-01 → 2022-09-30 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥76.06 | 2022-07-01 → 2022-09-30d | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥231.32 | 2021-01-01 → 2021-12-31 | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥233.5 | 2021-01-01 → 2021-09-30 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥64.97 | 2021-07-01 → 2021-09-30d | Cons. | Basic earnings loss per share IFRS |
| EPS (diluted) | ¥204.63 | 2022-01-01 → 2022-09-30 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥76.04 | 2022-07-01 → 2022-09-30d | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥231.15 | 2021-01-01 → 2021-12-31 | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥233.34 | 2021-01-01 → 2021-09-30 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥64.8 | 2021-07-01 → 2021-09-30d | Cons. | Diluted earnings loss per share IFRS |
| Equity ratio | 72.1% | at 2022-09-30 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 71.3% | at 2021-12-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 70.5% | at 2021-09-30 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 88
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2022-01-01 → 2022-09-30 | ¥126.1bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2022-07-01 → 2022-09-30 | ¥43.4bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2022-01-01 → 2022-09-30 | ¥94.2bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2022-07-01 → 2022-09-30 | ¥31.6bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2022-01-01 → 2022-09-30 | ¥31.9bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2022-07-01 → 2022-09-30 | ¥11.8bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2022-01-01 → 2022-09-30 | ¥9.9bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2022-07-01 → 2022-09-30 | ¥2.0bn |
| Reconciling Itemsreconciling | revenue | 2022-01-01 → 2022-09-30 | −¥32.0bn |
| Reconciling Itemsreconciling | revenue | 2022-07-01 → 2022-09-30 | −¥11.9bn |
| Reconciling Itemsreconciling | revenue intersegment | 2022-01-01 → 2022-09-30 | −¥32.0bn |
| Reconciling Itemsreconciling | revenue intersegment | 2022-07-01 → 2022-09-30 | −¥11.9bn |
| Reconciling Itemsreconciling | segment profit | 2022-01-01 → 2022-09-30 | −¥34.8bn |
| Reconciling Itemsreconciling | segment profit | 2022-07-01 → 2022-09-30 | −¥12.0bn |
| jpcrp040300-q3r_E21183-000Consumer Productsreportable segment | revenue | 2022-01-01 → 2022-09-30 | ¥27.0bn |
| jpcrp040300-q3r_E21183-000Consumer Productsreportable segment | revenue | 2022-07-01 → 2022-09-30 | ¥10.3bn |
| jpcrp040300-q3r_E21183-000Consumer Productsreportable segment | revenue external | 2022-01-01 → 2022-09-30 | ¥27.0bn |
| jpcrp040300-q3r_E21183-000Consumer Productsreportable segment | revenue external | 2022-07-01 → 2022-09-30 | ¥10.3bn |
| jpcrp040300-q3r_E21183-000Consumer Productsreportable segment | revenue intersegment | 2022-01-01 → 2022-09-30 | ¥18m |
| jpcrp040300-q3r_E21183-000Consumer Productsreportable segment | revenue intersegment | 2022-07-01 → 2022-09-30 | ¥12m |
| jpcrp040300-q3r_E21183-000Consumer Productsreportable segment | segment profit | 2022-01-01 → 2022-09-30 | ¥5.6bn |
| jpcrp040300-q3r_E21183-000Consumer Productsreportable segment | segment profit | 2022-07-01 → 2022-09-30 | ¥3.8bn |
| jpcrp040300-q3r_E21183-000Nutraceuticalsreportable segment | revenue | 2022-01-01 → 2022-09-30 | ¥325.6bn |
| jpcrp040300-q3r_E21183-000Nutraceuticalsreportable segment | revenue | 2022-07-01 → 2022-09-30 | ¥119.9bn |
| jpcrp040300-q3r_E21183-000Nutraceuticalsreportable segment | revenue external | 2022-01-01 → 2022-09-30 | ¥325.6bn |
| jpcrp040300-q3r_E21183-000Nutraceuticalsreportable segment | revenue external | 2022-07-01 → 2022-09-30 | ¥119.9bn |
| jpcrp040300-q3r_E21183-000Nutraceuticalsreportable segment | revenue intersegment | 2022-01-01 → 2022-09-30 | ¥18m |
| jpcrp040300-q3r_E21183-000Nutraceuticalsreportable segment | revenue intersegment | 2022-07-01 → 2022-09-30 | ¥7m |
| jpcrp040300-q3r_E21183-000Nutraceuticalsreportable segment | segment profit | 2022-01-01 → 2022-09-30 | ¥49.8bn |
| jpcrp040300-q3r_E21183-000Nutraceuticalsreportable segment | segment profit | 2022-07-01 → 2022-09-30 | ¥21.6bn |
| jpcrp040300-q3r_E21183-000Pharmaceuticalsreportable segment | revenue | 2022-01-01 → 2022-09-30 | ¥819.3bn |
| jpcrp040300-q3r_E21183-000Pharmaceuticalsreportable segment | revenue | 2022-07-01 → 2022-09-30 | ¥290.0bn |
| jpcrp040300-q3r_E21183-000Pharmaceuticalsreportable segment | revenue external | 2022-01-01 → 2022-09-30 | ¥819.3bn |
| jpcrp040300-q3r_E21183-000Pharmaceuticalsreportable segment | revenue external | 2022-07-01 → 2022-09-30 | ¥290.0bn |
| jpcrp040300-q3r_E21183-000Pharmaceuticalsreportable segment | segment profit | 2022-01-01 → 2022-09-30 | ¥84.5bn |
| jpcrp040300-q3r_E21183-000Pharmaceuticalsreportable segment | segment profit | 2022-07-01 → 2022-09-30 | ¥32.3bn |
| —segment total | revenue | 2022-01-01 → 2022-09-30 | ¥1.30T |
| —segment total | revenue | 2022-07-01 → 2022-09-30 | ¥463.7bn |
| —segment total | revenue external | 2022-01-01 → 2022-09-30 | ¥1.27T |
| —segment total | revenue external | 2022-07-01 → 2022-09-30 | ¥451.8bn |
| —segment total | revenue intersegment | 2022-01-01 → 2022-09-30 | ¥32.0bn |
| —segment total | revenue intersegment | 2022-07-01 → 2022-09-30 | ¥11.9bn |
| —segment total | segment profit | 2022-01-01 → 2022-09-30 | ¥149.7bn |
| —segment total | segment profit | 2022-07-01 → 2022-09-30 | ¥59.7bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2021-01-01 → 2021-09-30 | ¥110.8bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2021-07-01 → 2021-09-30 | ¥36.9bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2021-01-01 → 2021-09-30 | ¥82.3bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2021-07-01 → 2021-09-30 | ¥26.5bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2021-01-01 → 2021-09-30 | ¥28.4bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2021-07-01 → 2021-09-30 | ¥10.4bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2021-01-01 → 2021-09-30 | ¥12.2bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2021-07-01 → 2021-09-30 | ¥2.8bn |
| Reconciling Itemsreconciling | revenue | 2021-01-01 → 2021-09-30 | −¥28.5bn |
| Reconciling Itemsreconciling | revenue | 2021-07-01 → 2021-09-30 | −¥10.4bn |
| Reconciling Itemsreconciling | revenue intersegment | 2021-01-01 → 2021-09-30 | −¥28.5bn |
| Reconciling Itemsreconciling | revenue intersegment | 2021-07-01 → 2021-09-30 | −¥10.4bn |
| Reconciling Itemsreconciling | segment profit | 2021-01-01 → 2021-09-30 | −¥33.6bn |
| Reconciling Itemsreconciling | segment profit | 2021-07-01 → 2021-09-30 | −¥11.8bn |
| jpcrp040300-q3r_E21183-000Consumer Productsreportable segment | revenue | 2021-01-01 → 2021-09-30 | ¥24.1bn |
| jpcrp040300-q3r_E21183-000Consumer Productsreportable segment | revenue | 2021-07-01 → 2021-09-30 | ¥8.9bn |
| jpcrp040300-q3r_E21183-000Consumer Productsreportable segment | revenue external | 2021-01-01 → 2021-09-30 | ¥24.1bn |
| jpcrp040300-q3r_E21183-000Consumer Productsreportable segment | revenue external | 2021-07-01 → 2021-09-30 | ¥8.9bn |
| jpcrp040300-q3r_E21183-000Consumer Productsreportable segment | revenue intersegment | 2021-01-01 → 2021-09-30 | ¥17m |
| jpcrp040300-q3r_E21183-000Consumer Productsreportable segment | revenue intersegment | 2021-07-01 → 2021-09-30 | ¥8m |
| jpcrp040300-q3r_E21183-000Consumer Productsreportable segment | segment profit | 2021-01-01 → 2021-09-30 | ¥5.8bn |
| jpcrp040300-q3r_E21183-000Consumer Productsreportable segment | segment profit | 2021-07-01 → 2021-09-30 | ¥2.5bn |
| jpcrp040300-q3r_E21183-000Nutraceuticalsreportable segment | revenue | 2021-01-01 → 2021-09-30 | ¥280.1bn |
| jpcrp040300-q3r_E21183-000Nutraceuticalsreportable segment | revenue | 2021-07-01 → 2021-09-30 | ¥104.8bn |
| jpcrp040300-q3r_E21183-000Nutraceuticalsreportable segment | revenue external | 2021-01-01 → 2021-09-30 | ¥280.0bn |
| jpcrp040300-q3r_E21183-000Nutraceuticalsreportable segment | revenue external | 2021-07-01 → 2021-09-30 | ¥104.7bn |
| jpcrp040300-q3r_E21183-000Nutraceuticalsreportable segment | revenue intersegment | 2021-01-01 → 2021-09-30 | ¥33m |
| jpcrp040300-q3r_E21183-000Nutraceuticalsreportable segment | revenue intersegment | 2021-07-01 → 2021-09-30 | ¥12m |
| jpcrp040300-q3r_E21183-000Nutraceuticalsreportable segment | segment profit | 2021-01-01 → 2021-09-30 | ¥45.8bn |
| jpcrp040300-q3r_E21183-000Nutraceuticalsreportable segment | segment profit | 2021-07-01 → 2021-09-30 | ¥19.0bn |
| jpcrp040300-q3r_E21183-000Pharmaceuticalsreportable segment | revenue | 2021-01-01 → 2021-09-30 | ¥721.0bn |
| jpcrp040300-q3r_E21183-000Pharmaceuticalsreportable segment | revenue | 2021-07-01 → 2021-09-30 | ¥248.5bn |
| jpcrp040300-q3r_E21183-000Pharmaceuticalsreportable segment | revenue external | 2021-01-01 → 2021-09-30 | ¥721.0bn |
| jpcrp040300-q3r_E21183-000Pharmaceuticalsreportable segment | revenue external | 2021-07-01 → 2021-09-30 | ¥248.5bn |
| jpcrp040300-q3r_E21183-000Pharmaceuticalsreportable segment | segment profit | 2021-01-01 → 2021-09-30 | ¥128.0bn |
| jpcrp040300-q3r_E21183-000Pharmaceuticalsreportable segment | segment profit | 2021-07-01 → 2021-09-30 | ¥34.5bn |
| —segment total | revenue | 2021-01-01 → 2021-09-30 | ¥1.14T |
| —segment total | revenue | 2021-07-01 → 2021-09-30 | ¥399.0bn |
| —segment total | revenue external | 2021-01-01 → 2021-09-30 | ¥1.11T |
| —segment total | revenue external | 2021-07-01 → 2021-09-30 | ¥388.6bn |
| —segment total | revenue intersegment | 2021-01-01 → 2021-09-30 | ¥28.5bn |
| —segment total | revenue intersegment | 2021-07-01 → 2021-09-30 | ¥10.4bn |
| —segment total | segment profit | 2021-01-01 → 2021-09-30 | ¥191.8bn |
| —segment total | segment profit | 2021-07-01 → 2021-09-30 | ¥58.7bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 835
| Item | Context | Value | Unit |
|---|---|---|---|
| Intersegment revenue IFRS | Prior1QuarterDuration | － | JPY |
| Revenue IFRS | Prior1QuarterDuration_jpcrp040300-q3r_E21183-000PharmaceuticalsReportableSegmentMember | 248506000000 | JPY |
| Revenue IFRS | Prior1QuarterDuration_jpcrp040300-q3r_E21183-000NutraceuticalsReportableSegmentMember | 104760000000 | JPY |
| Revenue IFRS | Prior1QuarterDuration_jpcrp040300-q3r_E21183-000ConsumerProductsReportableSegmentMember | 8904000000 | JPY |
| Revenue IFRS | Prior1QuarterDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 36858000000 | JPY |
| Revenue IFRS | Prior1QuarterDuration_ReportableSegmentsMember | 399030000000 | JPY |
| Revenue IFRS | Prior1QuarterDuration_ReconcilingItemsMember | -10428000000 | JPY |
| Revenue IFRS | Prior1QuarterDuration | 388602000000 | JPY |
| Operating profit loss IFRS | Prior1QuarterDuration_jpcrp040300-q3r_E21183-000PharmaceuticalsReportableSegmentMember | 34476000000 | JPY |
| Operating profit loss IFRS | Prior1QuarterDuration_jpcrp040300-q3r_E21183-000NutraceuticalsReportableSegmentMember | 18964000000 | JPY |
| Operating profit loss IFRS | Prior1QuarterDuration_jpcrp040300-q3r_E21183-000ConsumerProductsReportableSegmentMember | 2466000000 | JPY |
| Operating profit loss IFRS | Prior1QuarterDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 2829000000 | JPY |
| Operating profit loss IFRS | Prior1QuarterDuration_ReportableSegmentsMember | 58737000000 | JPY |
| Operating profit loss IFRS | Prior1QuarterDuration_ReconcilingItemsMember | -11776000000 | JPY |
| Operating profit loss IFRS | Prior1QuarterDuration | 46961000000 | JPY |
| Revenue from external customers IFRS | CurrentQuarterDuration_jpcrp040300-q3r_E21183-000PharmaceuticalsReportableSegmentMember | 290040000000 | JPY |
| Revenue from external customers IFRS | CurrentQuarterDuration_jpcrp040300-q3r_E21183-000NutraceuticalsReportableSegmentMember | 119853000000 | JPY |
| Revenue from external customers IFRS | CurrentQuarterDuration_jpcrp040300-q3r_E21183-000ConsumerProductsReportableSegmentMember | 10323000000 | JPY |
| Revenue from external customers IFRS | CurrentQuarterDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 31595000000 | JPY |
| Revenue from external customers IFRS | CurrentQuarterDuration_ReportableSegmentsMember | 451811000000 | JPY |
| Revenue from external customers IFRS | CurrentQuarterDuration_ReconcilingItemsMember | － | JPY |
| Revenue from external customers IFRS | CurrentQuarterDuration | 451811000000 | JPY |
| Intersegment revenue IFRS | CurrentQuarterDuration_jpcrp040300-q3r_E21183-000PharmaceuticalsReportableSegmentMember | － | JPY |
| Intersegment revenue IFRS | CurrentQuarterDuration_jpcrp040300-q3r_E21183-000NutraceuticalsReportableSegmentMember | 7000000 | JPY |
| Intersegment revenue IFRS | CurrentQuarterDuration_jpcrp040300-q3r_E21183-000ConsumerProductsReportableSegmentMember | 12000000 | JPY |
| Intersegment revenue IFRS | CurrentQuarterDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 11836000000 | JPY |
| Intersegment revenue IFRS | CurrentQuarterDuration_ReportableSegmentsMember | 11856000000 | JPY |
| Intersegment revenue IFRS | CurrentQuarterDuration_ReconcilingItemsMember | -11856000000 | JPY |
| Intersegment revenue IFRS | CurrentQuarterDuration | － | JPY |
| Revenue IFRS | CurrentQuarterDuration_jpcrp040300-q3r_E21183-000PharmaceuticalsReportableSegmentMember | 290040000000 | JPY |
| Revenue IFRS | CurrentQuarterDuration_jpcrp040300-q3r_E21183-000NutraceuticalsReportableSegmentMember | 119860000000 | JPY |
| Revenue IFRS | CurrentQuarterDuration_jpcrp040300-q3r_E21183-000ConsumerProductsReportableSegmentMember | 10336000000 | JPY |
| Revenue IFRS | CurrentQuarterDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 43431000000 | JPY |
| Revenue IFRS | CurrentQuarterDuration_ReportableSegmentsMember | 463668000000 | JPY |
| Revenue IFRS | CurrentQuarterDuration_ReconcilingItemsMember | -11856000000 | JPY |
| Revenue IFRS | CurrentQuarterDuration | 451811000000 | JPY |
| Operating profit loss IFRS | CurrentQuarterDuration_jpcrp040300-q3r_E21183-000PharmaceuticalsReportableSegmentMember | 32277000000 | JPY |
| Operating profit loss IFRS | CurrentQuarterDuration_jpcrp040300-q3r_E21183-000NutraceuticalsReportableSegmentMember | 21627000000 | JPY |
| Operating profit loss IFRS | CurrentQuarterDuration_jpcrp040300-q3r_E21183-000ConsumerProductsReportableSegmentMember | 3846000000 | JPY |
| Operating profit loss IFRS | CurrentQuarterDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 1981000000 | JPY |
| Operating profit loss IFRS | CurrentQuarterDuration_ReportableSegmentsMember | 59733000000 | JPY |
| Operating profit loss IFRS | CurrentQuarterDuration_ReconcilingItemsMember | -12031000000 | JPY |
| Operating profit loss IFRS | CurrentQuarterDuration | 47701000000 | JPY |
| Document title cover page | FilingDateInstant | Original text (Japanese)四半期報告書 | |
| Clause of stipulation cover page | FilingDateInstant | Original text (Japanese)金融商品取引法第24条の４の７第１項 | |
| Place of filing cover page | FilingDateInstant | Original text (Japanese)関東財務局長 | |
| Filing date cover page | FilingDateInstant | 2022-11-02 | |
| Quarterly accounting period cover page | FilingDateInstant | Original text (Japanese)第15期第３四半期（自 2022年７月１日 至 2022年９月30日） | |
| Company name cover page | FilingDateInstant | Original text (Japanese)大塚ホールディングス株式会社 | |
| Company name in english cover page | FilingDateInstant | Otsuka Holdings Co., Ltd. |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 16 of 16 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |